Category Archives: USPTO Practice and Policy

USPTO will “Fast Track” Cancer Immunotherapy Applications

Posted on July 5, 2016 by Warren Woessner

On June 29, 2016, Director Lee promulgated rules to implement a one-year pilot program to effectively grant “Fast Track” status to applications with at least one claim to treating cancer using immunotherapy. (A copy of this document can be found … Continue reading →

Posted in USPTO Practice and Policy | Tagged , , , , , , , | Leave a comment

URGENT – COMMENTS DEADLINE EXTENDED

Posted on June 27, 2014 by Warren Woessner

The deadline for Myriad-Mayo comments has been extended by a month. Info on the USPTO website and can be found here.  

Posted in USPTO Practice and Policy | Tagged , , , , , , , , | Leave a comment

Top Ten IP Stories from 2013

Posted on December 16, 2013 by Warren Woessner

I admit it, I like lists, even completely subjective ones like this one, that is tilted toward patent law and prep/pros. So in no particular order, except for number one, here we go:   Myriad [Add your pun title here!]. … Continue reading →

Posted in Patent Eligible Subject Matter, Stem Cells/Cloning, USPTO Practice and Policy | Tagged , , , , , , , , | Leave a comment

Michelle Lee becomes (Acting) Under Secretary of Commerce for Intellectual Property

Posted on December 12, 2013 by Warren Woessner

Michelle Lee joined the USPTO as Director of the Silicon Valley Patent Office in 2012 (and apparently got her Reg. No. that year), after working as Deputy General Counsel of Google, and at Fenwick & West and Keker & Van … Continue reading →

Posted in USPTO Practice and Policy | Tagged , , , , , | Leave a comment